查詢結果分析
相關文獻
- 肝臟移植治療之免疫抑制劑
- Experience of Using FK 506 as a Rescue Therapy for Refractory Hepatic Allograft Rejection
- Emergent Orthotopic Liver Transplantation for Subfulminant Hepatic Failure: A Case Report
- 肝臟移植之病例用藥探討
- Tarolimus (Prograf[feb9])心臟肝臟腎臟移植的主要防衛武器
- 肝臟移植術後使用Tacrolimus與神經併發症之處置
- 評估肝臟移植病人使用Tacrolimus更換劑型的臨床療效及安全性
- 肝臟移植後神經精神併發症探討
- 急性肝衰竭的治療選擇--NAC
- 藥師介入肝臟移植病人照護之成效
頁籤選單縮合
題 名 | 肝臟移植治療之免疫抑制劑=Immuonsuppressants in the Treatment of Liver Transplantation |
---|---|
作 者 | 許雅婷; 謝東呈; | 書刊名 | 秀傳醫學雜誌 |
卷 期 | 12:1/2 2013.06[民102.06] |
頁 次 | 頁63-76 |
分類號 | 418.29、418.29 |
關鍵詞 | 肝臟移植; 免疫抑制劑; 肝衰竭; Liver transplantation; Immunosuppressive agents; Liver failure; |
語 文 | 中文(Chinese) |
中文摘要 | 肝臟移植已成為急性或慢性肝病末期患者唯一的治療選項。近年來,此項手術之適應症、禁忌症、手術技術及術後處置也愈趨瞭解及進步。肝臟移植成功率之提昇主要歸功於多種選擇性免疫抑制劑的臨床應用,可因大幅度地減少急性排斥的發生率,進而改善病人術後之短期及長期的預後。但是,尚待解決的部份為此類免疫抑制劑之長期毒性,其可造成心血管、神經性、及腎疾病等併發症。本文將詳述近來應用於肝臟移植之術前及術後之免疫抑制劑的種類及其作用機轉,並提供此項手術術前受贈病人的評估及選擇之相關資訊。 |
英文摘要 | Liver transplantation is the therapeutic option of choice for acute and chronic end-stage liver disease. The indications and contraindications for liver transplantation have become established, as has the operative and post-operative management. Its success can largely be attributed to the generation of selective immunosuppressive agents, which resulted in a dramatic reduction in the incidence of acute rejection and improvements in the short- and long-term outcomes of patients. However, the unresolved limitation of current immunosuppressive agents is long-term toxicity, which results in an increase incidence and severity of cardiovascular, neurological and renal diseases. This review will present currently available immunosuppressive agents used in the perioperative and post-operative period of liver transplantation and provide a clinical approach to evaluation of patients, with emphasis on transplant recipient selection and complications. |
本系統中英文摘要資訊取自各篇刊載內容。